Advance on immunotherapy and prognosis of Guillain-Barré syndrome / 中华实用儿科临床杂志

ABSTRACT

Guillain-Barré syndrome (GBS) is an acute onset immune-mediated polyradiculoneuropathy, and it is the most frequent cause of acute flaccid paralysis.Intravenous immunoglobulin and plasma exchange are proved to be an effective treatment.Despite the efficacy of immunotherapy, a significant number of patients have a poor prognosis, leaving behind severe dysfunction and even death.Therefore, biomarkers and prognostic models are needed to accurately predict outcome, which could help the early recognition of patients with poor outcomes, which may potentially be-nefit from individualized treatments.So, new development of immunotherapy and prognostic evaluation of GBS were summarized in this paper, in order to provide the evidence for clinical diagnosis and treatment.